Published in Expert Opin Drug Saf on November 01, 2007
Safety and efficacy of paliperidone extended-release in acute and maintenance treatment of schizophrenia. J Cent Nerv Syst Dis (2011) 1.15
Weight gain, obesity, and psychotropic prescribing. J Obes (2011) 1.02
A retrospective observational study of the effectiveness of paliperidone palmitate on acute inpatient hospitalization rates. Int Clin Psychopharmacol (2015) 0.86
Paliperidone extended-release: does it have a place in antipsychotic therapy? Drug Des Devel Ther (2011) 0.84
Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study. Ann Gen Psychiatry (2008) 0.80
Paliperidone ER in the Treatment of Borderline Personality Disorder: A Pilot Study of Efficacy and Tolerability. Depress Res Treat (2011) 0.76
Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology (2002) 1.23
Functional and structural brain correlates of theory of mind and empathy deficits in schizophrenia. Schizophr Res (2009) 1.14
Psychopathological and neuropsychological correlates of source monitoring impairment in schizophrenia. Psychiatry Res (2007) 0.99
Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. Int J Neuropsychopharmacol (2005) 0.97
Influence of catechol-O-methyltransferase Val158Met polymorphism on neuropsychological and functional outcomes of classical rehabilitation and cognitive remediation in schizophrenia. Neurosci Lett (2007) 0.96
The Brief Assessment of Cognition in Schizophrenia. Normative data for the Italian population. Neurol Sci (2008) 0.93
Criteria for symptom remission revisited: a study of patients affected by schizophrenia and schizoaffective disorders. BMC Psychiatry (2013) 0.83
HTTLPR functional polymorphism in schizophrenia: executive functions vs. sustained attention dissociation. Prog Neuropsychopharmacol Biol Psychiatry (2009) 0.83
Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment. Int J Neuropsychopharmacol (2004) 0.83
Cognitive dysfunction and glutamate reuptake: effect of EAAT2 polymorphism in schizophrenia. Neurosci Lett (2012) 0.81
Cerebral D2 and 5-HT2 receptor occupancy in Schizophrenic patients treated with olanzapine or clozapine. J Psychopharmacol (2004) 0.81
Genomics and epigenomics in novel schizophrenia drug discovery: translating animal models to clinical research and back. Expert Opin Drug Discov (2014) 0.80
Effect of 5-HT1A-receptor functional polymorphism on Theory of Mind performances in schizophrenia. Psychiatry Res (2010) 0.80
Theory of mind and emotion processing training for patients with schizophrenia: preliminary findings. Psychiatry Res (2012) 0.79
Self-awareness of cognitive functioning in schizophrenia: patients and their relatives. Psychiatry Res (2012) 0.79
Long-term remission in schizophrenia and schizoaffective disorder: results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Ther Adv Psychopharmacol (2013) 0.79
COMT and STH polymorphisms interaction on cognition in schizophrenia. Neurol Sci (2014) 0.79
The comprehension of idiomatic expressions in schizophrenic patients. Neuropsychologia (2009) 0.78
Clozapine-induced hypersensitivity myocarditis. Chest (2004) 0.78
Premorbid functioning and treatment response in recent-onset schizophrenia: prospective study with risperidone long-acting injectable. J Clin Psychopharmacol (2011) 0.78
The effect of verbalization strategy on Wisconsin Card Sorting Test performance in schizophrenic patients receiving classical or atypical antipsychotics. BMC Psychiatry (2006) 0.77
Patterns of evidence integration in schizophrenia and delusion. Psychiatry Res (2012) 0.77
COMT Val158Met and 5-HT1A-R -1019 C/G polymorphisms: effects on the negative symptom response to clozapine. Pharmacogenomics (2015) 0.77
Saitohin polymorphism and executive dysfunction in schizophrenia. Neurol Sci (2011) 0.77
Genetic dissection of drug effects in clinical practice: CLOCK gene and clozapine-induced diurnal sleepiness. Neurosci Lett (2004) 0.76
Exploring effects of EAAT polymorphisms on cognitive functions in schizophrenia. Pharmacogenomics (2014) 0.76
Theory of Mind intervention for outpatients with schizophrenia. Neuropsychol Rehabil (2013) 0.76
Catechol-O-methyltransferase (COMT) genotype biases neural correlates of empathy and perceived personal distress in schizophrenia. Compr Psychiatry (2012) 0.75
The COMT Val158Met polymorphism moderates the association between cognitive functions and white matter microstructure in schizophrenia. Psychiatr Genet (2016) 0.75